Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage biotechnology company developing first-in-classi targeted ...

The company is preparing for the Phase 3 study start in the first quarter of 2025BRISBANE, Calif., Oct. 10, 2024 (GLOBE ...

Ministers have been accused of “cutting” the RAF’s next generation fighter programme by 10 per cent this year as Rachel ...

Bob Dylan has always had an air of mystery surrounding him, but even he didn't think it was worth fans reading into the ...

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Tempest Therapeutics (TPST – Research Report). The ...

A significant temperature drop of 5 to 6 degrees and strong northerly winds in the Aegean are the key features of the weather ...

A former RuPaul's Drag Race competitor is on the mend after a shocking injury sent her to the hospital. Tempest DuJour, who ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and $47.00 stock price target for Tempest Therapeutics (NASDAQ:TPST) following the biotech firm's announcement of a drug supply agreement with ...

Gollancz has snapped up Tempest, the first adult standalone novel from Victoria Aveyard, the author of the YA series Red Queen (Orion) and Realm Breaker (Orion), in a seven-figure pre-empt.

BRISBANE, Calif. - Tempest Therapeutics, Inc. (NASDAQ:TPST), a biotechnology firm focused on cancer treatments, has reached an agreement with pharmaceutical giant Roche to progress a Phase 3 trial ...